NCT01813552View on ClinicalTrials.gov

To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

Chronic Hepatitis C Infection

Interventions

DRUG

Samatasvir

Samatasvir 150 mg oral tablets (50mg x 3), single dose

DRUG

Omeprazole

40 mg delayed-release oral capsules, once daily

DRUG

Ritonavir

100 mg oral tablets, once daily

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01813552 - To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006) | Biotech Hunter | Biotech Hunter